Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Favipiravir tablet composition

A technology of favipiravir tablet and favipiravir, which is applied in the directions of drug combination, pill delivery, antiviral agent, etc., can solve the problem of poor fluidity of favipiravir, poor water solubility of favipiravir, and easy pitting of tablets, etc. question

Inactive Publication Date: 2018-02-27
WEIHAI GUANBIAO INFORMATION TECH
View PDF2 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Tests have found that favipiravir has poor water solubility. Chinese published patent application CN105687152A discloses a fast-release preparation, and patent document CN104288154B discloses a composition containing micron-sized favipiravir
These methods solve the dissolution problem to some extent, but due to the poor fluidity of favipiravir, the prepared tablets are prone to pitting, and the dissolution rate of the tablets tends to decline as the storage time prolongs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1 Favipiravir 200g containing D90 less than 40 microns and D50 26 microns, microcrystalline cellulose 24g, lactose 18g, polyethylene glycol 6000 8g, sodium lauryl sulfate 1.3g, meteorological dioxide Silicon 2g, magnesium stearate 1g. Prepare 1000 tablets according to the preparation method described in the technical scheme.

Embodiment 2

[0019] Embodiment 2, containing 200g of Favipiravir whose D90 is less than 40 microns and D50 is 33 microns, microcrystalline cellulose 45g, lactose 10g, polyethylene glycol 6000 16g, sodium lauryl sulfate 0.8g, meteorological two Silicon oxide 5g, magnesium stearate 2.5g. Prepare 1000 tablets according to the preparation method described in the technical scheme.

Embodiment 3

[0020] Example 3, 200g of favipiravir containing D90 less than 40 microns and D50 of 30 microns, microcrystalline cellulose 35g, lactose 15g, polyethylene glycol 6000 12g, sodium lauryl sulfate 1.0g, gas phase two Silicon oxide 3.0g, magnesium stearate 1.8g. Prepare 1000 tablets according to the preparation method described in the technical scheme.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a favipiravir tablet composition, which belongs to the technical field of pharmaceutical preparations. The technical scheme of the present invention is: a kind of favipiravir tablet composition, in the composition of unit dose, containing D90 is less than 40 microns, and D50 is 200mg of favipiravir at 26-33 microns, microcrystalline cellulose 24‑45mg, lactose 10‑18mg, macrogol 6000 8‑16mg, sodium lauryl sulfate 0.8‑1.3mg, meteorological silica 2‑5mg, magnesium stearate 1‑2.5mg. The invention provides a qualified favipiravir tablet, which solves the defects that the tablet has pits and the dissolution rate decreases as the storage time prolongs.

Description

technical field [0001] The invention relates to a favipiravir tablet composition, which belongs to the technical field of pharmaceutical preparations. Background technique [0002] Influenza (abbreviated as influenza) is an acute respiratory infection caused by influenza virus, and it is also a highly contagious and fast-spreading disease. It is mainly spread through droplets in the air, person-to-person contact or contact with contaminated items. Typical clinical symptoms are: sudden onset of high fever, general pain, significant fatigue and mild respiratory symptoms. Generally, autumn and winter are the high-incidence period, and the complications and death caused by it are very serious. The disease is caused by influenza virus, which can be divided into three types: A (A), B (B), and C (C). Type A virus often undergoes antigenic mutation, is highly contagious, spreads rapidly, and is prone to large-scale epidemics. [0003] Favipiravir (Favipiravir), the chemical name ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4965A61K9/20A61K47/38A61K47/10A61K47/26A61K47/04A61K47/20A61K47/12A61P11/00A61P31/16
CPCA61K31/4965A61K9/2009A61K9/2013A61K9/2018A61K9/2031A61K9/2054
Inventor 孙爱梅
Owner WEIHAI GUANBIAO INFORMATION TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com